Reviewer #1 (Remarks to the Author):
In the present manuscript the authors presented a novel too l for in vivo tracing of cells combining C re-LoxP system and PET technology using sr39tk reporter gene. They could show the use of this tool for tracing specific group of cells such as platelets, T lymphocytes, and cardiomyocytes. Moreover, they demonstrated the use of this tool for tracing cells in two disease -contexts consisting of inflammation and myocardial ischemia.
This study is of general interest and provided a new tool for in vivo phenotyping although some limitations has to be faced, however this will importantly advance the investigation of cell-fate in developmental and/or diseases related questions.
The manuscript is well writing and the figure well prepared. However, this review feels that some few points have to be addressed before being considered for publication:
1-Minor: Expression of mT before C re recombination (in case of inducible C re) or in non -specific cells are not clearly shown.
2-Minor: Rosa-mT/sr39tk appears in page 1 line 97 and the explanation of "mT" is later in line 108. Major: a C re positive R26[+/+] is missing, especially after the data presented in Suppl. 5 where pure WT and C re negative are similar and only the C re positive R26[sr39tk/+] showed an effect in cell numbers in Lymph nodes, Spleen and Thymus. It is well-described that (and depending on the mouse background) C re expression alone can cause some alteration independent of the GOI. Therefore, the sentence in page 7: line 181, "Thus, the reduced number of T cells in C D4/sr39tk mice was apparently mainly caused by expression of sr39tk and not by expression of C re recombinase." Is overestimated.
4-Minor: Page 8: line 233, why 1 mg Tamoxifen for 5 days and why after 4 weeks? 5-General Major: The limitation of this technique in C re -lox-inducible models has to be clearly discussed, especially in proliferative cells. They cannot be traced when they proliferate after induction of the recombination and therefore will dilute the effect of tracing; well-designed protocols have to be providing for it. As in the present manuscript, in the case of myocardial ischemia i.e., it remains the question open whether newly formed Mhy6-expressing cells will dilute the labelling and the reductio n of ([18F]FHBG) uptake and will underestimate the rate of cells viability.
6-Suppl. Figure 3 and 4
Minor: Animals are named differently as stated in the text "mice are denoted "C re promoter/lacZ" mice" and in the figure they are denoted "promoter -C re". In suppl. Figure 3 the WT bgal staining (control) is missing.
Major: A co-staining will be more suitable to claim that the bgal positive cells are of a certain nature (ie. C D31, Mac3). Better magnifications are necessary for stating the staining in th e smooth muscle cells rather than endothelial of bgal. Scale bars are missing. Figure 3B does not seem to reflect this observation. Please discuss. This is correct. One animal showed relatively increased (but not really 'high') uptake into the untreated ear. We have mentioned and discussed this observation on page 8 (line 220-224): 'Autoradiography detected elevated tracer uptake also in the non-challenged right ears of sr39tk+ mice, in particular in one of the three sr39tk+ animals analyzed (Fig. 3c) . This was likely due to scratching and transfer of TNCB from the left to the right ear, thereby, inducing inflammation also in the "non-challenged" right ear.'
The PET images shown in Fig. 3b (left) are not from this mouse. For clarification, we prepared the figure below for the reviewer. It shows the individual time courses of [ 18 F]FHBG uptake measured with PET in three individual animals (left; we added the uptake ratio between TNCB-treated and control ear in red) in comparison to the respective ear autoradiographs taken on day 20 (right). Indeed, the mouse with elevated tracer uptake in the non-challenged right ear as revealed by autoradiography on day 20 did also show increased PET signals in the untreated ear (first animal, open circles). This PET signal was similar to the TNCB-treated ear on day 20, but much weaker than the PET signals at the peak of inflammation in the challenged left ears at day 13. In general, changes in [
18 F]FHBG uptake of the TNCB-treated ears over time were much higher than in untreated ears. Therefore, the comparably minor changes within the untreated ears are visible in the autoradiographs, where animals are shown individually, but not in the original Fig. 3b (right) , where the average of all animals was shown.
Based on the reviewer's comment, we have now revised Fig (6) The authors should discuss ectopic activity of CD4-Cre mice in skeletal muscle. Is this unique to CD4 promoter leakiness? Do other promoters also have similar ectopic activity? Please discuss.
We think that the weak (but significant) activity of CD4-Cre mice that was detected in skeletal muscle in the biodistribution analysis (Suppl. Fig. 2e ) is not due to activity in skeletal muscle fibers, but likely caused by activity in vascular smooth muscle cells of the blood vessels, which are also the reason for ectopic activity of CD4-Cre mice in the heart. This has been stated/discussed in the manuscript (line 166-168): 'Ectopic activity of the CD4-Cre line in some vascular smooth muscle cells could also explain the weak but significant tracer uptake that was detected ex vivo in skeletal muscle (Supplementary Fig. 2e ).' Does the reviewer suggest to include a general discussion on Cre/lox vs CRISPR/Cas technology? If so, we feel this would significantly extend the manuscript, which is already close to the word limit. Also, we are not sure as to how such general discussion would relate to the PET reporter mouse model we describe in this paper. If the reviewer thinks it is absolutely required, please advise us more specifically, and we will add it. Yes, thank you for pointing this out. Changed accordingly.
Reviewer #3:
(1) Minor: Expression of mT before Cre recombination (in case of inducible Cre) or in non-specific cells are not clearly shown.
We have extended Supplementary Fig. 1 We apologize if the nomenclature we used to describe mouse genotypes caused confusion. We added several clarifications all over the manuscript and hope that with these additions it will be clear to the reader that we are using the '+' symbol to indicate respective wild type alleles:
(1 Supplementary  Fig. 5b-d We fully agree with the reviewer that Cre expression alone may cause phenotypes that are independent of the expression of Cre-responsive (reporter) genes. Indeed, to test for the effect of Cre expression alone (in the absence of sr39tk), we have analyzed in Supplementary Fig. 5b -e also CD4-Cre transgenic mice that did NOT carry the sr36tk reporter gene. In contrast to CD4-Cre/sr39tk mice (that expressed Cre and sr39tk in T cells), CD4-Cre mice (that only expressed Cre in T cells) did not show major reductions in T cell numbers. These results led us to the conclusion 'Thus, the reduced number of T cells in CD4/sr39tk mice was apparently mainly caused by expression of sr39tk and not by expression of Cre recombinase' (line 185).
To clarify the genotypes used in these experiments and to relativize our observations, Fig. 5b-d) . Thus, the reduced number of T cells we observed in CD4/sr39tk mice was apparently mainly caused by expression of sr39tk and not by expression of Cre recombinase.' [1972] [1973] [1974] [1975] [1976] [1977] [1978] [1979] [1980] [1981] [1982] . In this publication, loss of myocardial gene expression induced by Myh6-CreER T2 was analyzed 2 weeks after the last Tamoxifen treatment. However, to avoid potential side effects caused by Tamoxifen or vehicle (oil), and to reduce stress to the animals, we performed myocardial infarction 4 weeks after finishing Tamoxifen injection.
(5) General Major: The limitation of this technique in Cre-lox-inducible models has to be clearly discussed, especially in proliferative cells. They cannot be traced when they proliferate after induction of the recombination and therefore will dilute the effect of tracing; well-designed protocols have to be providing for it. As in the present manuscript, in the case of myocardial ischemia i.e., it remains the question open whether newly formed Mhy6-expressing cells will dilute the labelling and the reduction of ([18F]FHBG) uptake and will underestimate the rate of cells viability.
We understand this comment in a way that the reviewer is concerned about the fact that once-labeled cells may lose the reporter gene (or reporter gene expression) when they proliferate. If this is the reviewer's concern, we must respectfully disagree. A central strength of our approach of Cre-mediated activation of reporter gene expression is its stability independent of cell proliferation. The key is that the reporter transgene is stably integrated into the cell's genome and, therefore, inherited to both daughter cells upon mitotic cell division without any "dilution", even over multiple rounds of cell division. As Cre-mediated activation of the reporter gene is based on an irreversible modification of the chromosomal DNA (i.e., excision of the mT-encoding gene cassette), it is very unlikely that cells lose reporter gene expression upon proliferation. The commonly used and well-characterized CAG promoter drives sr39tk expression after Cre-mediated activation of the reporter gene; this promoter is known for strong constitutive/cell-type independent gene expression. Therefore, it is unlikely that reporter gene expression is reduced or lost even if cells change their phenotype upon proliferation. The background behind our strategy for stable cell labeling has been mentioned several times in the manuscript. We also hope that changes in the introduction (lines 85ff; see also comment 3 from Reviewer #1) clarify that cell labeling is not lost upon proliferation of the initially labeled cells.
The reviewer also points out that, in case of myocardial infarction, newly formed cells may dilute the labeled cells so that measurement of [
18 F]FHBG uptake could lead to an underestimation of myocardial viability. We agree with the reviewer. In the current study, we were not able to discern whether heart tissue was regenerated via proliferation of pre-existing cardiomyocytes (which should have been labeled) or formation of new cardiomyocytes from non-cardiomyocyte progenitor cells (which were presumably not labeled). Fig. 3 
and 4).'
Major: A co-staining will be more suitable to claim that the bgal positive cells are of a certain nature (ie. CD31, Mac3). Better magnifications are necessary for stating the staining in the smooth muscle cells rather than endothelial of bgal. Scale bars are missing
The reviewer suggests to perform double staining of X-Gal positive cells with CD31 or Mac3 to better demonstrate the nature of the positive cells. The reviewer is correct. This would be the ideal way to demonstrate the identity of the positive cells. However, co-staining with the X-Gal stain is rather difficult due to the intensity and color of the X-Gal precipitate. Since CD31 and Mac3 antibodies are specific for endothelial cells and macrophages, respectively, we have revised Supplementary Fig. 4 as suggested by the reviewer, and include higher magnifications as insets into each picture. In these new insets, it is clearly depicted that X-Gal stains the smooth muscle cells of the blood vessels as well as macrophages, whereas CD31 stains the endothelial cells sparing the smooth muscle. In addition, we have included a higher magnification of the macrophages in the lung stained with X-Gal. As also pointed out by the reviewer, we have now added the scale bars in all microphotographs. To allow better evaluation of tracer uptake, we have prepared a new Supplementary Fig. 7 that shows all 'cross-sections' of the hearts in VLA orientation for every PET acquisition for both tracers. Images are in the resolution of the original datasets.
